Jinze Li
李金泽
Jinze Li (李金泽, Dr. Robert Li) is the founder and CEO of Ze'an Biopharmaceutical (则正生物 / LTZ), a biotech company developing myeloid cell engager therapies. He established the company and led it through a $40 million Series A+ round in April 2025, followed by a $50 million upfront partnership with GSK announced later that year . elsewhere's corpus does not cover his personal background or prior career in detail.
AI-generated — may contain errors, please verify.
Jinze LiPerson
李金泽
渲染中…
Mentioned in 3 articles
Coverage
$50 Million Upfront Payment! Zeon Secures Another Partnership with Global Pharma Giant | BlueRun Ventures Family Headlines
Ze'an Partners with Another Global Pharma Giant
Zean completes $40 million Series A+ round to accelerate development of myeloid cell engager pipeline | BlueRun Ventures Family
Focusing on unmet clinical needs in major disease areas such as cancer and autoimmune diseases.
